{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T09:40:55Z","timestamp":1648546855905},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"15","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["MMW - Fortschritte der Medizin"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s15006-019-0844-6","type":"journal-article","created":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T15:02:52Z","timestamp":1567868572000},"page":"33-36","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Der neue Zoster-Totimpfstoff: Wen, wann, wie impfen?"],"prefix":"10.1007","volume":"161","author":[{"given":"Ulrich","family":"Seybold","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,7]]},"reference":[{"key":"844_CR1","unstructured":"Ultsch B, Weidemann F, Koch J and Siedler A. Projektbericht - Modellierung von epidemiologischen und gesundheits\u00f6konomischen Effekten von Impfungen zur Pravention von Herpes zoster. Verf\u00fcgbar unter \n                    https:\/\/www.rki.de\/DE\/Content\/Infekt\/Impfen\/ImpfungenAZ\/Zoster\/Modellierung_Zoster_Impfung.pdf\n                    \n                  . Robert Koch-Institut 2017"},{"key":"844_CR2","first-page":"333","volume":"34","author":"Robert Koch-Institut.","year":"2017","unstructured":"Robert Koch-Institut. Empfehlungen der Standigen Impfkommission (STIKO) am Robert Koch-Institut - 2017\/2018. Epid Bull 2017;34:333\u2013380","journal-title":"Epid Bull"},{"key":"844_CR3","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","volume":"372","author":"H Lal","year":"2015","unstructured":"Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015;372:2087\u201396","journal-title":"N Engl J Med"},{"key":"844_CR4","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","volume":"375","author":"AL Cunningham","year":"2016","unstructured":"Cunningham AL, Lal H, Kovac M, et al. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med 2016;375:1019\u201332","journal-title":"N Engl J Med"},{"key":"844_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","volume":"67","author":"KL Dooling","year":"2018","unstructured":"Dooling KL, Guo A, Patel M, et al. Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. MMWR Morb Mortal Wkly Rep 2018;67:103\u2013108","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"844_CR6","doi-asserted-by":"publisher","first-page":"220","DOI":"10.14745\/ccdr.v44i09a06","volume":"44","author":"R Warrington","year":"2018","unstructured":"Warrington R, Ismail S and National Advisory Committee on Immunization. Summary of the NACI Update on Herpes Zoster Vaccines. Can Commun Dis Rep 2018;44:220\u2013225","journal-title":"Can Commun Dis Rep"},{"key":"844_CR7","first-page":"541","volume":"50","author":"Robert Koch-Institut.","year":"2018","unstructured":"Robert Koch-Institut. Mitteilung der St\u00e4ndigen Impfkommission (STIKO) am RKI: Wissenschaftliche Begr\u00fcndung zur Empfehlung einer Impfung mit dem Herpes zoster-subunit-Totimpfstoff. Epid Bull 2018;50:541\u2013567","journal-title":"Epid Bull"},{"key":"844_CR8","doi-asserted-by":"publisher","first-page":"S415","DOI":"10.1093\/ofid\/ofx163.1039","volume":"4","author":"K Pauksens","year":"2017","unstructured":"Pauksens K, Volpe S, Schwarz TF, et al. Persistence of Immune Response to an Adjuvanted Varicella-Zoster Virus Subunit Candidate Vaccine for up to Year 9 in Older Adults. Open Forum Infectious Diseases 2017;4:S415\u2013S415","journal-title":"Open Forum Infectious Diseases"},{"key":"844_CR9","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1080\/21645515.2018.1442162","volume":"14","author":"TF Schwarz","year":"2018","unstructured":"Schwarz TF, Volpe S, Catteau G, et al. Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults. Hum Vaccin Immunother 2018;14:1370\u20131377","journal-title":"Hum Vaccin Immunother"},{"key":"844_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","volume":"16","author":"AM Didierlaurent","year":"2017","unstructured":"Didierlaurent AM, Laupeze B, Di Pasquale A, Hergli N, Collignon C and Garcon N. Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert Rev Vaccines 2017;16:55\u201363","journal-title":"Expert Rev Vaccines"},{"key":"844_CR11","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1093\/infdis\/jix482","volume":"216","author":"K Grupping","year":"2017","unstructured":"Grupping K, Campora L, Douha M, et al. Immunogenicity and Safety of the HZ\/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine. J Infect Dis 2017;216:1343\u20131351","journal-title":"J Infect Dis"},{"key":"844_CR12","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/infdis\/jiu606","volume":"211","author":"EM Berkowitz","year":"2015","unstructured":"Berkowitz EM, Moyle G, Stellbrink HJ, et al. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1\/2a randomized, placebo-controlled study. J Infect Dis 2015;211:1279\u201387","journal-title":"J Infect Dis"},{"key":"844_CR13","doi-asserted-by":"publisher","first-page":"S415","DOI":"10.1093\/ofid\/ofx163.1040","volume":"4","author":"L Oostvogels","year":"2017","unstructured":"Oostvogels L. Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in Adults with Hematologic Malignancies: A Phase III, Randomized Clinical Trial. Open Forum Infectious Diseases 2017;4:S415\u2013S415","journal-title":"Open Forum Infectious Diseases"},{"key":"844_CR14","volume-title":"Clin Infect Dis","author":"P Vink","year":"2019","unstructured":"Vink P, Ramon Torrell JM, Sanchez Fructuoso A, et al. Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: a Phase III, Randomized Clinical Trial. Clin Infect Dis 2019"},{"key":"844_CR15","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1016\/S0140-6736(18)30631-7","volume":"391","author":"DJ Winston","year":"2018","unstructured":"Winston DJ, Mullane KM, Cornely OA, et al. Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2018;391:2116\u20132127","journal-title":"Lancet"},{"key":"844_CR16","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1093\/cid\/cix484","volume":"65","author":"M Eberhardson","year":"2017","unstructured":"Eberhardson M, Hall S, Papp KA, et al. Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults With Autoimmune Disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Clin Infect Dis 2017;65:1174\u20131182","journal-title":"Clin Infect Dis"}],"container-title":["MMW - Fortschritte der Medizin"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15006-019-0844-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s15006-019-0844-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15006-019-0844-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T10:34:35Z","timestamp":1600857275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.springermedizin.de\/doi\/10.1007\/s15006-019-0844-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":16,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["844"],"URL":"https:\/\/doi.org\/10.1007\/s15006-019-0844-6","relation":{},"ISSN":["1438-3276","1613-3560"],"issn-type":[{"value":"1438-3276","type":"print"},{"value":"1613-3560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"7 September 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}